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Vestibular migraine (VM) is an increasingly recognized pathology yet remains as an
underdiagnosed cause of vestibular disorders. While current diagnostic criteria are
codified in the 2012 Barany Society document and included in the third edition
of the international classification of headache disorders, the pathophysiology of this
disorder is still elusive. The Association for Migraine Disorders hosted a multidisciplinary,
international expert workshop in October 2020 and identified seven current care gaps
that the scientific community needs to resolve, including a better understanding of
the range of symptoms and phenotypes of VM, the lack of a diagnostic marker, a
better understanding of pathophysiologic mechanisms, as well as the lack of clear
recommendations for interventions (nonpharmacologic and pharmacologic) and finally,
the need for specific outcome measures that will guide clinicians as well as research
into the efficacy of interventions. The expert group issued several recommendations to
address those areas including establishing a global VM registry, creating an improved
diagnostic algorithm using available vestibular tests as well as others that are in
development, conducting appropriate trials of high quality to validate current clinically
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available treatment and fostering collaborative efforts to elucidate the pathophysiologic
mechanisms underlying VM, specifically the role of the trigemino-vascular pathways.
Keywords: vestibular migraine, chronic migraine (CM), trigemino-vascular pathway, vertigo-pathophysiology,
vestibular disorders

INTRODUCTION

identify research gaps in VM with the goal of identifying
initiatives that would advance research in this field. The basis for
convening this meeting was to evaluate the state of diagnosis,
pathophysiology, and treatment of VM and furthermore,
to answer some of the many challenging and unanswered
questions related to this disease. Participants included experts
from several medical specialties including otolaryngology,
neurotology, neurology, audiology, and physical therapy. Based
on the discussions at the workshop, this report highlights existing
care gaps, supporting evidence and recommendations to address
these gaps.

Vestibular migraine (VM) is a migraine disorder which
presents with heterogeneous symptomatology and with several
overlapping phenotypes. VM remains largely underdiagnosed
and knowledge of its pathophysiology is limited (1). It is typically
characterized by recurrent vestibular symptoms associated with
migraine symptoms (headaches of a migraine quality and/or
photophobia and phonophobia and/or visual aura) and has been
considered among the most common causes of dizziness (2).
Risk factors associated with VM include young age (below 40
years), female sex, a history of anxiety and depression and prior
head trauma (3). Previously, other terms have been used for
VM which include benign recurrent vertigo, migraine-associated
dizziness, migraine-associated vertigo, migrainous vertigo, and
migraine-related vestibulopathy.
Epidemiological data confirm that migraine-related
syndromes that include a spectrum of vestibular symptoms
are the most common cause of vertigo and dizziness in adults
and children (4). While VM can develop at any age, it generally
affects persons with a long-established history of migraine
disease (5). It is diagnosed with an average delay of 8.4 years after
the first onset of migraine (6).
Since the early development of VM as a distinct diagnosis
in the 1980’s, the estimated prevalence of VM in the general
population is not precisely known because of the general
underdiagnosis of this condition (7). According to Neuhauser
et al. VM accounts for about 7% of patients seen in dizziness
clinics and 9% of patients seen in migraine clinics (5). Other
case series report that 16–34% of patients seen for dizziness in
an otolaryngology clinic have a vestibular migraine (8–10). A
national telephone interview survey in Germany by Neuhauser
et al. estimated the 1-year and a lifetime prevalence of VM to be
0.89% and 1% in the adult general population (11). In a more
recent study by Formeister et al. within the United States (U.S.),
based on a population-based survey from the 2008 National
Health Interview Survey (NHIS), the prevalence of VM in adults
was estimated to be 2.7% (3). This is higher than the estimated
prevalence of benign paroxysmal positional vertigo (BPPV) of
1.6% and that of Meniere’s disease (MD) (0.2–0.5%) (12, 13).
On October 4, 2020, the Association of Migraine Disorders
(AMD) hosted a half-a-day virtual workshop to discuss and

CARE GAP 1: LACK OF UNIVERSALLY
ACCEPTED RANGE OF VM PHENOTYPES
AND UNCLEAR SPECTRUM OF VM
DISORDERS
In 2012, diagnostic criteria for VM were put forth by the
International Headache Society (ICHD-3) and Bárány society
which replaced the historical most accepted Neuheuser criteria
(14, 15). Currently, there are multiple classification criteria for
VM. The most restrictive is the ICHD-3 listed in Table 1 which
acknowledges only definite VM. The Bárány society criteria
makes provision for a separate category called probable vestibular
migraine (Table 1) and in clinical practice, most patients who
benefit from migraine therapy would fall in this latter category.
Current ICHD-3 and Bárány Society diagnostic criteria of
vestibular migraine leave many endophenotypes/subtypes of VM
unrecognized. For instance, dizziness per se is not exclusively
a vestibular symptom qualifiable for VM diagnosis. To be
considered, dizziness must be triggered by head motion and
must be associated with nausea or other migraine symptoms. The
current ICHD-3 symptoms that are symptoms qualifiable exclude
certain dizziness phenotypes such as rocking and displacement
in place seen in disorders such as Mal de debarquement
(MDDS), Persistent Postural Perceptual Dizziness (PPPD), along
with visual motion sensitivity. The rationale for specifying
moderate or severe symptom severity is likely included to avoid
duplicative diagnoses, or misattribution of dizziness symptoms
(i.e., imbalance) when the primary symptom is headache.
Evidence from current and future studies will help to elucidate
the features of vestibular symptoms in VM and revise that point
of the diagnostic criteria.
Epidemiological studies have documented the relationship
between migraine headache and vertigo, suggesting an
association between the two, yet the underlying neuronal
pathophysiology is relatively unknown (16–18). Migraine
headache typically predates the onset of vertigo with the mean
duration of 8 years (6). Mean age of onset of headaches is

Abbreviations: VM, vestibular migraine; MC, migraine cephalgia; BPPV,
benign paroxysmal positional vertigo; MD, Meniere’s Disease; MDDS, Mal de
debarquement syndrome; PPPD, persistent postural perceptual dizziness; TOAEs,
transient evoked otoacoustic emissions; DPOAEs, distortion product otoacoustic
emissions; ABR, auditory brainstem response; VEMP, vestibular-evoked myogenic
potentials; SVV, subjective visual vertical; SVH, subjective visual horizontal; TVS,
trigemino-vascular system; CGRP, calcitonin gene-related peptide; SSRIs, selective
serotonin reuptake inhibitors; SNRIs, serotonin and norepinephrine reuptake
inhibitors; PROMs, patient reported outcomes measures.
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TABLE 1 | Diagnostic criteria for VM as proposed by International Headache Society and Bárány Society.
Vestibular Migraine:
A. At least five episodes with vestibular symptoms lasting 5 min to 72 h.
B. Current or previous history of migraine with or without aura.
C. One or more migraine features with at least 50% of the vestibular episodes:
a. Headache with at least two of: one sided location, pulsating quality, moderate or severe pain intensity, aggravation by routine physical activity
b. Photophobia and phonophobia
c. Visual aura
D. Not better accounted for by another vestibular diagnosis or ICHD diagnosis
Probable Vestibular Migraine:
A. At least five episodes with vestibular symptoms lasting 5 min to 72 h.
B. Only one of the criteria B and C for vestibular migraine is fulfilled.
C. Not better accounted for by another vestibular diagnosis or ICHD diagnosis.

positional, visually induced, or head-motion induced, and are
described in many ways by patients. Additionally, the timing
of the attacks can also vary from minutes to days making the
diagnosis of this disease very complex. For instance, as awareness
of the relationship of migraine and vertigo has grown, many
patients previously assigned a diagnosis of basilar migraine
are now known to have VM. Basilar migraine is now better
known as migraine with brainstem aura where vertigo and at
least one other brainstem neurologic symptom (excluding motor
weakness) must precede the headaches.

28 years old and mean age of dizziness onset is 49 years old.
Patients with a synchronous or a combined presentation are
younger (19). Additionally, the prevalence of vertigo is high in
migraine patients and similarly, patients with dizziness often
have a history of migraine (20). In the Migraine and Neck Pain
Study, 30% of adult patients reported episodic vertigo anytime
during the migraine attack with 16% having vertigo at the
onset of headache, with 10% patients reporting episodic vertigo
within 2 h before the headache and 3% patients experiencing
episodic vertigo as a premonitory symptom up to 48 h before
the headache. Nausea and vomiting were found to be associated
with headaches and vertigo (19). Almost a third of these patients
in the Migraine and Neck Pain Study could be diagnosed with
VM or at least probable VM, according to the Bárány society
criteria, supporting the association between migraine headache
and vertigo (20). Symptoms such as cyclic vomiting, recurrent
abdominal pain and atopy are also commonly observed in
migraine patients (21). Considering there is an overlap of
symptoms, both migraine and vestibular migraine may be part
of a disease spectrum sharing an underlying pathophysiology.
Recommendation 1: (a) Establish a global VM patient registry
that maintains uniform quality data and documents the natural
history of vestibular symptoms in relation to migraine disease,
(b) Refine the international, evidence-based diagnostic criteria
for VM to account for the various symptoms reported by
VM patients.

Several comorbidities are also known to be associated with
VM including neurotologic conditions such as BPPV and
MD. The symptoms of these conditions may overlap with
those of VM symptoms and confuse the diagnosis of VM,
especially when patients with other vestibular disorders may
have superimposed, secondary migraine symptoms and not have
VM as a primary cause of their symptoms (22). Psychiatric
comorbidities, including anxiety, somatoform dizziness/chronic
subjective dizziness may coexist with VM as well (23, 24).
Furthermore, acknowledging that patients may have more
than one vestibular diagnosis contributing to their symptoms
is essential to providing accurate treatment and conducting
accurate research (25).
There are suggestions that migraine mechanisms can affect
the inner ear, that BPPV and MD can be complications of a
migraine process, and that these conditions are potentially in
pathophysiologic continuum with VM in which some patients
manifest pure central disease, others manifest pure peripheral
disease, and others have manifestations of both (26, 27). Patients
with VM may exhibit tinnitus, aural pressure, and fluctuations in
hearing. Hearing loss however does not tend to progress as it does
in MD (28). Early on, MD patients may exhibit isolated episodic
vertigo without otologic symptoms. Despite having a formal
diagnostic criterion for VM and MD, it is becoming clearer that
the diagnostic criteria for VM need to be refined and broadened
(29). For instance, Frejo et al. define five endophenotypes for
MD: idiopathic or classic, posttraumatic/delayed, autoimmune,
familial or associated with migraine (30). The current ICHD3 criteria acknowledge that there are patients with features
of both disorders (with cochleovestibular symptoms of ear

CARE GAP 2: VM IS CURRENTLY
UNDERDIAGNOSED IN THE GENERAL
POPULATION AND MULTIPLE
ASSOCIATED CO-MORBIDITIES ARE
UNDERRECOGNIZED
Diagnosis for VM primarily relies on clinical history due to
the lack of clinically available and reliable diagnostic laboratory
tests. Since several epidemiological studies have supported the
relationship between migraine and VM, the diagnosis of VM is
very much dependent on the presence of migraine symptoms
(22). Symptoms of dizziness and vertigo may be spontaneous,
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vestibular migraines have caloric response asymmetry or may
have oculomotor deficits or positional nystagmus with central
features (39–41). While some studies points toward peripheral
dysfunction in the setting of vestibular migraine, one should bear
in mind that a caloric asymmetry can still indicate a separate
vestibular disorder or a preexisting vestibular dysfunction which
in itself may be a cause of migraines. Other observed patterns
include the fact that VM patients are less likely to complete a full
battery of vestibular tests and are more likely to develop an attack
following testing (42, 43).
Vestibular-evoked Myogenic Potentials (VEMPs), a measure
of saccular and utricular function, can separate in some instances
VM from MD but the data is not clear-cut and there are no
consistently reliable abnormalities (44–46). A recent systematic
review did not support the role of cervical VEMP alone to aid
in diagnosing VM (47). Rizk et al. (48) looked at the negative
predictive value of the presence of an oVEMP and/or cVEMP
response in patients presenting with a differential diagnosis of
VM vs MD and showed that a present response in this specific
clinical situation has a 93% negative predictive value. Subsequent
studies suggested using VEMPs as part of a diagnostic algorithm.
On the other hand, current research is looking into other
tools that could identify a patient with VM and differentiate
them from other pathologies, namely MD. Tests of perceptual
threshold, which are still not clinically available, show reduced
dynamic tilt thresholds in vestibular migraine patients (49). The
measurement of subjective visual vertical (SVV) and subjective
visual horizontal (SVH) can serve as diagnostic indicators of
dysfunction in spatial orientation (50). Abnormal SVV and
SVH measurements occur in a significant number of individuals
with VM, especially during head tilt where the brain is
challenged to maintain spatial orientation (51, 52). The larger
SVV errors in VM compared with healthy controls suggest
abnormal sensory integration for spatial orientation in these
patients (51). Thus, incorporating head-roll tilt during static
and dynamic SVV conditions rather than in the traditional
head upright position can produce more distinctive findings in
migraine patients.
The functional head impulse test with and without optokinetic
stimulation shows promise in identifying VM patients since
it highlights dynamic visual dependence which is a hallmark
manifestation of VM (53). The usefulness of this test in make a
differential diagnosis with MD is to be evaluated (54).
Finally, there has been a quest to identify a readily accessible
biomarker for VM. A recent study has identified a differential
proinflammatory signature separately for patients with VM and
MD where certain cytokines and chemokines were elevated.
These preliminary studies suggest VM can be differentially
diagnosed from healthy individuals and patients with MD using
a small cytokine panel retrieved from a blood sample (IL-1β,
IFNγ, CCL3, CCL22, and CXCL1) thereby improving the clinical
management of VM (55).
Recommendation 3: (a) Create an improved diagnostic
algorithm for VM using available vestibular function testing and
consider incorporating perceptual threshold testing into clinical
practice, (b) Pursue further research to identify a circulating
biomarker to differentiate VM from MD.

fullness/pressure, periodic or fluctuating tinnitus, fluctuating
hearing loss in the setting of vestibular migraine or of a migraine
disorder) and recommend treating the patients for MD especially
if there is compelling audiometric confirmation. In addition to
understanding the multiple phenotypic presentations of VM,
patients with classifiable peripheral disease such as MD and
recurrent BPPV responding to migraine management and with
migraine features during attacks should potentially be considered
to be on the same spectrum (31, 32). This broadening of
recognized symptoms should be expanded to include patients
with chronic rocking dizziness and patients with disorientation
in space, as these symptoms are commonly reported by migraine
patients. While MDDS is currently considered a separate
entity, it is the hallmark condition causing rocking dizziness.
Multiple studies show high prevalence of migraines especially in
“spontaneous mal de debarquement” as well as high prevalence
of new-onset headaches in patients with new onset MDDS
(8, 33, 34).
Recommendations 2: (a) Enhance provider education,
especially among practitioners who manage patients with
dizziness, around VM and its potential subtypes including
complexity of symptoms that may occur on a continuum, (b)
Consider refining ICD coding for VM and possible subtypes as
has been done for migraine headache.

CARE GAP 3: LACK OF A KNOWN
DIAGNOSTIC LABORATORY TESTING OR
AN OBJECTIVE MARKER AVAILABLE FOR
CLINICIANS
The current diagnostic criteria of VM are only clinical and based
on the identification of the features outlined in the consensus
of the International Headache and Bárány Societies in the
ICHD-3 (14, 15). There is no pathognomonic clinical sign for
vestibular migraine and there are no gold standard diagnostic
tests for VM.
However, certain paraclinical tests are administered in the
clinical setting. Auditory and vestibular testing has some value
in the comprehensive evaluation of these patients. Classic
audiometry can put in evidence a low frequency hearing loss
suggestive of MD or concomitant MD. Other audiometric tests
are not widely used in clinical practice. However, transient
evoked otoacoustic emissions (TOAEs), distortion product
otoacoustic emissions (DPOAEs), and auditory brainstem
response (ABR) at high and low repetition rate frequencies show
nonspecific abnormalities in nearly two thirds of patients with
chronic migraine (35).
In addition, while vestibular testing cannot identify the
presence of VM, it can put in evidence a concurrent
dysfunction such as uncompensated vestibular hypofunction
(due to peripheral or central mechanisms), comorbid BPPV as
well as utricular/saccular dysfunction (35). Additionally, certain
patterns can emerge on testing as well and help guide the
diagnosis and/or the treatment plan (36). For instance, motion
sensitive individuals tend to have longer time decay constants
on step velocity rotary chair testing (37, 38). Some patients with
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CARE GAP 4: PATHOPHYSIOLOGIC
MECHANISMS EXPLAINING THE VARIOUS
PHENOTYPES AND FORMS OF VM
(EPISODIC VS. CHRONIC) AS WELL AS
ASSOCIATED SYMPTOMS (SPATIAL
DISORIENTATION, HEARING LOSS,
VERTIGO) ARE STILL UNCLEAR

neural processing of sensory information, vestibular inputs, and
pain (56).
Functional imaging data suggests the involvement of the
multisensory vestibular thalamocortical networking in the
pathophysiology of VM (1, 58, 59). Dizziness and spatial
disorientation are thought to be caused by abnormal sensory
modulation or integration within the thalamocortical network
(1). Several findings indicate central dysfunction related to
vestibular processing in patients such as perceptual dysfunction,
abnormal spatial orientation during head tilt, elevated vestibuloperceptual threshold after adaptation to visual motion (51, 60).
These findings suggest that in general the perceptual functions of
vestibular system are on a spectrum with VM on one end with low
or distorted perception threshold and high level of symptoms (1).
While, on the other end of the spectrum, there are those with high
perceptual thresholds (such as ballet dancers) and low symptoms
who show shorter durations of vestibular ocular response and
perception of rotation (time constant) with whole body rotation
(1, 61). Thus, an effective treatment strategy can be envisioned
that could move patients toward the middle of the spectrum
by increasing motion perception thresholds. Therefore, gaining
insights into central processes that result in dizziness, vertigo,
and spatial disorientation is an important step toward devising
effective treatment strategies (1).
Altered activity of the vestibular system is thought to
cause vestibular ocular dysfunction or vestibular hypersensitivity
associated with migraine features (1). Also, a recent crosssectional study suggested that cortical interactions between the
visuo-vestibular system are abnormal in vestibular migraine
patients (1). Results from peripheral vestibular testing in VM
patients has shown inconsistent results indicating vestibular
dysfunction and some of this dysfunction could be related
to the modulation of inner ear function by migraine-related
mechanisms. Furthermore, the sensory neuroepithelia within
the vestibular sensory pathways are thought to be influenced
by a diverse number of neuroactive substances that may act to
enhance or inhibit the effect of the primary neurotransmitters
such as glutamate and acetylcholine (62).
In addition, it is also hypothesized that integration of canal
and otolith inputs for motion perception could be abnormal
in VM, a function that is mediated by the cerebellar nodulus
and uvula and/or possibly the thalamus (63). It was further
hypothesized that elevated levels of CGRP during and between
vertigo episodes could reduce Purkinje cell activity, thereby
disinhibiting the neurons in the vestibular nuclei that receive
their projections and contribute to the velocity storage network
(64). Velocity storage has been linked to the synthesis of canal
and otolith cues and motion sickness and aberrant control of this
network could contribute to the vertigo and motion intolerance
in VM (49, 63).
Finally, the vascular circulation of the inner ear receives
innervation from the trigeminal nerve through the basilar artery
and the anterior inferior cerebellar artery. Chemical and electrical
stimulations of the trigeminal nerve may cause a significant
increase in inner ear blood flow and neuroinflammation
- changes in intravascular permeability and plasma protein

In general, very little is known about the pathophysiology
of VM. Given the multiple potential interactions between
the trigeminal and vestibular systems, it is likely that VM
symptoms have a multifactorial etiopathophysiologic basis.
Several possible mechanisms have been proposed based on the
general understanding of migraine pathophysiology. Potential
involvement and interactions between the trigemino-vascular
system (TVS), nociceptive brain stem centers, thalamocortical
network, and vestibular system have also been suggested
to explain the underlying pathogenesis linking various VM
symptoms (1).
Headaches are thought to result from an increased activity
or sensitization within the TVS and nociceptive brainstem and
thalamocortical centers. Animal models of chronic migraine
suggest that migraine-mediated sensitization of the trigeminal
nuclei, through its neural projections to vestibular nuclei, might
affect the sensitivity of vestibular nuclei resulting in migraineassociated vestibular dysfunction (56). Certain neuropeptides
such as calcitonin gene-related peptide (CGRP) and substance
P cause neuroinflammation leading to pain or allodynia
(central sensitization) in migraine patients. Some of these
same neuropeptides (such as CGRP) are also expressed in the
vestibular system and could be involved in VM pathophysiology
(56). In fact, systemic CGRP injection has been shown to
cause light-aversion (photosensitivity) in mice which can be
blocked by CGRP antagonists or monoclonal antibodies (57).
Furthermore, using a rat model of chronic migraine, Zhang et al.
(56) demonstrated the possibility of sensitization of vestibular
nucleus neurons to impair vestibular function after chronic
migraine and were able to restore vestibular dysfunction in
following anti-CGRP treatment (56). An increase in CGRP levels
in both sensitized trigeminal and vestibular nuclei suggest that
CGRP may have a critical role in the transformation to chronic
sensitization. Therefore, just as CGRP enhances the abnormal
pain sensitivity, it is possible that it might also increase the
sensitivity of the balance system and can explain the spontaneous
or sustained nature of VM (56).
Trigeminal innervation of the labyrinth vessels links
the nociceptive trigeminal system to the vestibular system.
Connections between brainstem vestibular nuclei and the
structures that modulate trigeminal nociceptive inputs
throughout the brainstem may play some part in VM.
Neuroimaging techniques suggest an altered modulation in
the integration and processing of vestibular and nociceptive
information with the network from the vestibular sensors
through the brainstem to the cortex. In this context, genetic
variables can affect the excitatory–inhibitory balance involved in
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extravasation into the inner ear (65). Vasospasm of the cochlear
and/or vestibular branches of the internal auditory artery might
explain sudden episodes of hearing loss and/or vertigo associated
with migraine (49).
Recommendation 4: (a) Promote collaborative research
(between laboratory scientists and clinicians) to study central
and peripheral mechanisms of VM symptoms (b) Identify the
effect of modulating the TVS, possibly by blocking CGRP, in
the inner ear specifically and then understanding its effects on
neuroepithelium in the auditory and vestibular system to provide
some clues to VM pathophysiology.

vagal nerve neuromodulators can be helpful as well (72, 73).
Nutraceuticals have been proven to be effective in prevention of
migraine headaches have not yet been studied thoroughly studied
for VM.
The mainstay of the management of vestibular migraine is
prophylactic medication when VM attacks are frequent and
severe. Migraine headache prophylactic medications have been
traditionally used to treat VM and observational studies with
these medications have shown benefits (74). Pharmacological
drugs for VM have been used for acute treatment or as
preventative treatments and are classified into two groups based
on their mechanism of action. One class of drugs act on the
neurotransmitters and their receptors. The second class of drugs
act on voltage-gated channels (75). The details of the current
drugs used for treatment of VM along with their daily dosage
and common side effects have been reviewed extensively before
(74, 76, 77). Typically, the choice of medication for treating VM is
guided by its side effect profile and the comorbidities of patients.
Interestingly, these treatment recommendations have been based
on observational studies, physicians’ experiences, familiarity with
the medications, patient comorbidities and side effects of various
interventions (74, 78).
Treatment trials for VM are rare and only now starting
to emerge. Previously, only two randomized controlled trials
were conducted with triptans (rizatriptan and zolmitriptan)
specifically for acute attacks to VM and these provided limited
evidence for treating VM (79). A recent systematic review
and meta-analysis of 13 studies assessed the efficacy of various
therapies for prevention of VM. Treatment options analyzed
included antiepileptic drugs, calcium channel blockers, tricyclic
antidepressants, beta blockers, selective serotonin reuptake
inhibitors (SSRIs), serotonin and norepinephrine reuptake
inhibitors (SNRIs) and vestibular rehabilitation (78). All these
treatments showed improvement in measured outcomes, but
an established preferred treatment could not be determined
due to the heterogeneity of the VM symptoms and the lack of
standardized reporting on outcomes (8, 78, 80).
Experiencing vertigo can produce anxiety, therefore
treating or managing comorbidities, particularly mood
disorders, can help with vestibular symptoms (81). Tricyclic
antidepressants such as amitriptyline or nortriptyline, or
SSRIs and benzodiazepines such as clonazepam have been
recommended (82). SNRI have also been suggested as clinically
safe and effective for migraine as well as VM prophylaxis but
were considered inferior in response to other drugs (83).
CGRP monoclonal antibodies are novel therapies that
have been approved for either prevention or treatment of
migraine. Clinically we can assume that by controlling migraines
in patients with CGRP monoclonal antibodies, we may
be able to reduce or eliminate symptoms of VM. There is
currently an active single center pilot study with randomized
double-blinded placebo-controlled trial comparing the efficacy
and safety of galcanezumab to placebo in the treatment
of vestibular migraine (https://clinicaltrials.gov/ct2/show/
NCT04417361). Preliminary data from another monoclonal
antibody eptinezumab (NCT04152083) for prevention of chronic
migraine were positive, but it is yet to be approved by the FDA.

CARE GAP 5: LACK OF UNDERSTANDING
OF THE BIOLOGICAL DIFFERENCES
UNDERLYING GENDER DISPARITY IN VM
While VM can occur at any age and between both sexes, it peaks
in middle age and is 2–3 times more prevalent in women than
in men (6, 66, 67). A common pattern/typical patient seen in a
clinic is a woman with a history of classic or common migraines
with improved symptoms following menopause but presenting
with new-onset vestibular symptoms years after headaches have
diminished (1, 68).
Changes in hormonal levels can be associated with episodes
of vestibular migraine which can sometimes be observed in
the perimenstrual period (69–71). Vestibular symptoms in
women can also become more pronounced around the time of
perimenopause. Dizziness is a common symptom in the late
stage of menopausal transition and an unstable hormonal state
is considered to be its trigger. While the role of sex hormones
(estrogen and progesterone) in VM is not yet understood they
are thought to influence various neurotransmitter systems in
the brain that are associated with migraine activation such
as serotonergic, glutaminergic, GABAergic, noradrenergic, and
opioid systems (72).
Recommendation 5: Promote studies to understand
possible associations between hormonal changes and vestibular
symptoms across the lifespan.

CARE GAP 6: LACK OF APPROPRIATE
COMBINATION AF PHARMACOLOGIC
AND NONPHARMACOLOGIC MEASURES
TO TREAT VESTIBULAR MIGRAINE AS
WELL AS OF AN APPROPRIATE STEPWISE
MANAGEMENT ALGORITHM
The current treatment approach of the VM patient is not well
codified and is comprised of nonpharmacologic measures as well
as medications prescribed (for the most part) in an off-label
indication, and rehabilitative measures of uncertain potential.
Most measures are based on empiric evidence or extrapolated
from the treatment of typical migraine headaches.
Non-pharmacological measures such as diet, sleep hygiene
and avoidance of triggers are recommended the same way they
are for migraine headaches. Greater occipital nerve blocks and
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TABLE 2 | List of care gaps and recommendations for vestibular migraine proposed by the expert panel.
Care Gaps

Recommendations

1. Lack of universally accepted range of VM phenotypes
and unclear spectrum of VM disorders.

(1a) Establish a global VM patient registry that maintains uniform quality data and documents the natural
history of vestibular symptoms in relation to migraine disease.
(1b) Refine the international, evidence-based diagnostic criteria for VM to account for the various
symptoms reported by VM patients.

2. VM is currently underdiagnosed in the general
population and multiple associated co-morbidities are
underrecognized.

(2a) Enhance provider education, especially among practitioners who manage patients with dizziness,
around VM and its potential subtypes including complexity of symptoms that may occur on a continuum
(2b) Consider refining ICD coding for VM and possible subtypes as has been done for
migraine headache.

3. Lack of a known diagnostic laboratory testing or an
objective marker available for clinicians.

(3a) Create an improved diagnostic algorithm for VM using available vestibular function testing and
consider incorporating perceptual threshold testing into clinical practice.
(3b) Pursue further research to identify a circulating biomarker to differentiate VM from MD.

4. Pathophysiologic mechanisms explaining the various
phenotypes and forms of VM (episodic versus
chronic) as well as associated symptoms (spatial
disorientation, hearing loss, vertigo) are still unclear.

(4a) Promote collaborative research (between laboratory scientists and clinicians) to study central and
peripheral mechanisms of VM symptoms.
(4b) Identify the effect of modulating the TVS, possibly by blocking CGRP, in the inner ear specifically and
then understanding its effects on neuroepithelium in the auditory and vestibular system to provide some
clues to VM pathophysiology.

5. Lack of understanding of the biological differences
underlying gender disparity in VM.

5. Promote studies to understand possible associations between hormonal changes and vestibular
symptoms across the lifespan.

6. Lack of appropriate combination of pharmacologic
and nonpharmacologic measures to treat vestibular
migraine as well as of an appropriate stepwise
management algorithm.

(6a) Promote novel and evidence-based approaches for VM treatment.
(6b) Develop and publish guidelines on conducting and reporting randomized controlled trials of acute
and preventative treatment of VM modeled on available guidelines developed by the ICHD for migraine
cephalgia trials.
(6c) Conduct randomized control trials to study pharmaceutical and non-pharmaceutical approaches for
VM treatment.

7. Need for better Patient Reported Outcome Measure
(PROM) to quantify the impact of VM or any
intervention on the patient’s quality of life.

7. Create and validate a VM disease-specific PROM instrument using psychometrically valid methods

Serotonin receptor 5-HTIF is believed to regulate the release
of CGRP from vestibular nuclei (84). In 2019, FDA approved 5HTIF receptor agonist lasmiditan for treatment of acute migraine
(85). Considering Lasmiditan was effective in treating headache
and photophobia, it may have the potential to serve as a
prophylactic treatment for VM.
Vestibular rehabilitation and natural activities that can
enhance spatial perception and body coordination, such as
ping-pong and dancing can be helpful to alleviate symptoms
in VM patients. Vestibular rehabilitation can be useful when
there is associated vestibular dysfunction or comorbid BPPV
but also when patients develop maladaptive strategies that lead
to visual dependence or loss of confidence in balance (82).
More studies are warranted to truly understand the benefits
of vestibular rehabilitation and other rehabilitative strategies
in the VM patients (86). Rehabilitation should be conducted
by an experienced therapist who will be able to slowly and
incrementally increase the dose of the exercises to avoid causing
significant symptoms since these patients are generally very
motion sensitive.
Finally, current treatment strategies are focused on reducing
the burden of vestibular and headache symptom burden. Often
overlooked symptoms such as “brain fog,” “foggy headed,”
“head in a cloud” and “difficulty thinking clearly” correlate
with worse scores on cognitive scales and are best classified
as forms of cognitive dysfunction. Cognitive dysfunction may
be a cause of ongoing disability in VM patients. There is
currently no clear intervention that would help address this
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specific symptomatology although cognitive therapy or other
rehabilitative measures could be explored (48, 87).
Recommendation: (a) Promote novel and evidence-based
approaches for VM treatment, (b) Develop and publish
guidelines on conducting and reporting randomized controlled
trials of acute and preventative treatment of VM modeled
on available guidelines developed by the ICHD for migraine
cephalgia trials (88), (c) Conduct randomized control trials to
study pharmaceutical and non-pharmaceutical approaches for
VM treatment.

CARE GAP 7: NEED FOR BETTER PATIENT
REPORTED OUTCOME MEASURE (PROM)
TO QUANTIFY THE IMPACT OF VM OR
ANY INTERVENTION ON THE PATIENT’S
QUALITY OF LIFE
Vestibular disorders are a major cause of absenteeism and loss
of productivity at work (89). In addition, vestibular disorders
in general and VM in particular have been associated with
sleep disturbances, psychiatric comorbidities and cognitive
dysfunction. Furthermore, chronic migraine, by itself, is
considered the second most prevalent cause of disability
worldwide (90). Given the prevalence of these disorders and their
impact on patients, it can be inferred that vestibular disorders,
particularly VM can have a major impact on a patients’ quality
of life.
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also may be used as an outcome measure of interventions. The
recommendations proposed by this group to address the care
gaps, listed together in Table 2, broadly fall into three categories,
namely establishing a VM registry, advancing clinical research on
VM and providing education. Establishing a registry can allow
for creating a treatment algorithm, a diagnostic algorithm as well
as retrieval of high-quality data provided an ICD code is created.
Advancing clinical research is critical as many knowledge gaps
remain to this day. Encouraging and fostering collaborations
with basic researchers can promote an understanding of
the underlying pathophysiological mechanisms of VM and
its connection to chronic migraine and other comorbidities.
Although treatments are available, there is a critical need for
evidence-based approaches to treating and managing VM. More
clinical trials for novel treatments are needed with appropriate
outcome measures along with comparative efficacy studies for
existing treatments. Finally, broader education and awareness
on VM, its endophenotypes and its relation to comorbidities is
clearly needed for clinicians who treat patients for dizziness.

The current available tools such as the dizziness handicap
inventory, and PROMs are not disease specific and do not capture
the extent of the condition’s impact (91–93). There is also a
need for better PROMs for research study design (critical to
improving success in NIH funded projects). Efforts are being
made in that area with Sharon et al. recently describing a potential
new instrument VM-PATHI (94). In addition to being able to
gauge the severity of the condition, in the absence of an objective
marker for diagnosis, we currently also rely on patients’ reports to
gauge the response to any intervention. PROMs are used in most
clinical trials as outcome measures. To this end, there is a need to
properly define appropriate outcome measures before designing
and studying treatment interventions.
Recommendation 7: Create and validate a VM
disease-specific PROM instrument using psychometrically
valid methods.

CONCLUDING STATEMENT
We have identified seven broad care gaps in our understanding
and management of vestibular migraine. There is a lack of
definition of endophenotypes of VM and underdiagnosis of
subjects with atypical symptoms or who do not fit the ICHD-3
criteria strictly. The absence of an objective diagnostic marker
contributes to those gaps as well as the insufficient knowledge
of pathogenesis including hormonal influence. Furthermore,
there is insufficient evidence of best treatment algorithms and
treatment is often initiated based on comorbidities and side
effect profile without clear evidence for a stepwise approach.
Finally, there is a need to develop an instrument that can capture
all the dimensions of the quality of life affected by the VM
condition; this will help gauge the severity of the condition but
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